Products from BPS Bioscience require a minimum order value above 400€
Encompassing Amino Acids: 19-328
Application: Useful for binding studies.
Assay Conditions: The assay was performed using a white 96-well Maxisorp plate precoated with IL-33 (#102419) at 100 ng/50 µl per well. Blocking Buffer 3 (#79743) and PBST were used for blocking and washing steps, respectively. For protein titration a serial dilution of IL1RL1 (#102451) at the highest concentration of 6 ng/µl (300 ng/reaction) was prepared in 1x PP-02 Assay Buffer (#82620). Diluted IL1RL1 was then added to the wells and plate was incubated at Room Temperature (RT) for 1 hour. The plate was then washed again and incubated with an anti-Fc-HRP conjugate (50 µl/well diluted 1000-fold in Blocking Buffer 3) was added for 1 hour at RT. After the final wash, ELISA ECL mix (Substrate A and Substrate B premixed 1:1 (#79670) was added to each well and chemiluminescence was read.
Background: IL-33 is a cytokine of the IL-1 family that is released in response to external triggers, such as trauma, allergen exposure and infections. IL-33 can be either on its reduced or oxidized state, which use different signaling pathways. When in its reduced state (IL33red) it binds to IL1RL1 ((interleukin 1 receptor like 1), also named IL-33R or ST2 (receptor serum-stimulated 2). IL1RL1 exists as both a membrane bound protein or a truncated soluble form. Binding of IL-33 to IL1RL1 initiated a signaling pathway that involves NF-κF (nuclear factor kappa-light-chain-enhancer of activated B cells) and MAPK (mitogen-activated protein kinase), and results in release of pro-inflammatory cytokine and chemokines. The soluble form of IL1RL1 can act as a decoy receptor for IL-33. Dysregulation in the levels of IL-33 is implicated in the pathology of inflammatory and infectious diseases, including COVID-19, COPD (chronic obstructive pulmonary disease) and asthma. The involvement of IL-33 in these diseases has made it a high value therapeutic target, with strategies such as antibodies being developed to inhibit the binding of IL-33 to its receptor. One example is tozorakimab (MEDI3506), from AstraZeneca, currently being evaluated as treatment for COPD. Further studies on IL-33 and its receptor will likely result in new therapies for IL-33 related disorders.
Description: Recombinant human ST2, also known IL1RL1 (interleukin 1 receptor like 1), transcript variant 1, encompassing amino acids 19-328. This construct contains at the C-terminus a Factor Xa site, followed by the Fc domain of a human IgG1, an Avi-Tag™. The recombinant protein was affinity purified.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol
Genbank: NM_016232.5
Host Cell Line: HEK293
Purity: ≥85%
Storage Stability: At least 6 months at –80°C.
Tags: Fc-Avi
Target: IL1RL1
Uniprot: Q01638
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
Deutsch
English
